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Hypertriglyceridemia in nephrotic (NS) and Nagase
analbuminemic rats (Analb) results from reduced triglyceride
clearance. NS and Analb have reduced or absent albumin,
reduced plasma oncotic pressure (p), but Analb lack
proteinuria. The heparin releasable lipoprotein lipase (LpL)
pool in both models is greatly reduced, suggesting reduced
LpL is related to low albumin or p and not proteinuria.
To determine the cause of endothelial LpL reduction, we
studied effectors of endothelial LpL (eLpL) levels from gene
expression, to delivery and endothelial binding. eLpL was
measured as heparin releasable activity. eLpL and secretion
rate was measured in isolated hearts perfused with heparin.
mRNA levels were measured in rat hearts by kinetic RT-PCR.
Finally, binding of 125I-LpL by competition assays rat
endothelial cells measured serum-induced changes in
affinity. eLpL in vivo was reduced in nephrotic and Analb rats.
While the eLpL pool was reduced in isolated perfused hearts,
neither LpL secretion by isolated hearts nor myocardial
mRNA was reduced in NS or Analb. Binding of LpL to RAEC
preincubated with serum from either NS or Analb was
reduced compared to control. LpL mRNA levels and release
rate was not altered in hearts from NS rats, while eLpL is
depleted, suggesting that reduced eLpL in NS is not the
result of reduced delivery. The finding that NS serum alters
LpL binding to RAEC suggests LpL depletion results from
decreased binding rather than defective delivery. This in turn
is a consequence of reduced serum albumin or p but does
not require proteinuria.
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Hypertriglyceridemia occurs commonly in the nephrotic
syndrome. While both increased secretion1 and decreased
catabolism2 of triglyceride-rich lipoproteins (TRL),3 includ-
ing4,5 chylomicrons and very low-density lipoproteins
(VLDL), have been reported, recent evidence suggests
reduced TRL catabolism is most important in establishing
their increased levels.6–9
We have demonstrated that proteinuria alters the structure
and function of both high-density lipoprotein and VLDL
contributing to decreased VLDL clearance.10,11 However, an
identical defect in chylomicrons uptake by perfused hearts
isolated from either analbuminemic (Analb) or nephrotic
rats (NS) rats suggests that an endothelial defect arising from
hypoalbuminemia even in the absence of proteinuria also
contributes to decreased lipoprotein clearance in both
models.10
Both the fractional and absolute rate of lipolysis of
exogenously administered chylomicrons is reduced in rats
with an experimental model of the nephrotic syndrome.2 The
catabolic defect8,12 persists in isolated tissue (heart),9
suggesting that a change in the endothelium contributes at
least in part to the reduced TRL catabolism. The rate-limiting
enzyme responsible for TRL triglyceride (TG) lipolysis,
lipoprotein lipase (LpL), is associated with the vascular
endothelium. Endothelial cells do not produce LpL directly.
Instead, it is produced by mesenchymal tissue – such as
myocardial and skeletal muscle, adipose tissue, and mono-
nuclear cells – and undergoes a process of translocation to the
endothelium.13 LpL is sorted in the Golgi and is directed to
either exocytosis or to intracellular degradation. Since
intracellular LpL reaches catalytic maturity as early as the
endoplasmic reticulum,14 nonsecreted LpL comprises tissue-
associated LpL activity that is not heparin releasable, and
confounds the use of total tissue LpL as marker for lipolytic
capacity. After LpL is released from the synthesizing cell, it
binds to heparan sulfate on the secreting cell, forming an
interstitial LpL pool. This binding is important because LpL’s
association with heparan sulfate imparts stability to the
enzyme.15 It is then translocated from the interstitial pool to
the vascular endothelium where it binds to heparan sulfate
moieties on the vascular endothelium forming an endothelial
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LpL pool. This endothelial bound pool is physiologically
relevant because only this pool is capable of interaction with
VLDL for lipolysis or internalization. Heparin can displace
LpL from its attachment to heparan sulfate moieties on the
vascular endothelium and release it from interstitial spaces
due to LpL’s higher affinity for heparin than for heparan
sulfate. Both the endothelial and interstitial pool then form
potential heparin releasable pools of LpL.
Total heparin releasable LpL has been reported to be
reduced in vivo both in experimental models of the nephrotic
syndrome2,7,9,16–18 and in nephrotic patients.19 These findings
suggest that a reduction in the activity of the endothelial LpL
pool plays a contributing role in reducing TRL clearance.
The mechanism responsible for the reduced endothelial LpL
pool is not established. Potential mechanisms include
reduction in synthesis, secretion, transport, or binding of
LpL to the endothelial surface. Additionally, it is unclear how
the mechanism(s) responsible for LpL depletion is associated
to the rest of the pathophysiology of the nephrotic syndrome.
It is not clear whether the LpL depletion results from
proteinuria per se, or if it is a consequence of reduced
albumin concentration or p. We studied LpL levels in two
models of reduced albumin concentration, rats with
hereditarily analbuminemia – the Nagase Analb rat and rats
with hypoalbuminemia resulting from urinary protein loss
(the nephrotic syndrome) to establish the effects of hypo-
albuminemia on LpL in the presence and absence of urinary
protein loss. Analb rats exhibit some aspects of nephrotic
syndrome although they lack proteinuria, including
increased levels of fibrinogen, macroglobulins, transferrin,
apolipoprotein A (apoA)-I20–23 as well as elevated plasma TG
and cholesterol and reduced heparin releasable LpL.8,16 Thus,
Analb rats serve as a model of nephrotic syndrome in the
absence of proteinuria. TG levels are significantly less in
Analb than in nephrotic animals consistent with a partial
defect in lipoprotein metabolism imparted by low albumin
levels alone in the absence of proteinuria.
In order to determine the mechanism of LpL depletion in
the nephrotic syndrome, we measured heparin releasable LpL
from intact nephrotic animals, having both reduced albumin
levels and proteinuria and Analb animals, having isolated
hypoalbuminemia in the absence of urinary protein loss as
well as LpL heparin inducible release, delivery and mRNA
levels in isolated hearts from these same groups of animals.
We also established the effect of serum from nephrotic and
Analb animals on the binding of LpL to endothelial cells.
RESULTS
Serum TG levels were significantly increased in NS rats
(257730 mg/dl in comparison to Analb (120717) and
control (30715 mg/dl). All three groups were significantly
different than one another (Po0.05).
Heparin releasable LpL
In both NS and Analb rats, total body releasable (in vivo)
heparin releasable LpL activity was reduced to 14.274.9 and
2.876.2%, respectively, of controls (Figure 1). Within the
nephrotic group itself, heparin releasable LpL activity was a
significant predictor of serum TG levels and accounted for
88% of the variability in serum TG levels (r2¼ 0.881,
P¼ 0.018), but heparin releasable LpL activity did not
correlate with serum TG in either Analb or control.
Myocardial LpL secretion
Similar to what was observed in the whole body, the release of
LpL from typical rat hearts perfused continuously with
heparin is shown in Figure 2. We found that most control
hearts had an initial peak at 1–3 min post-heparin, and an
additional peak at 3–4 min. The additional peak was fused
with the first peak in three control and five NS rats and all
six Analb rats. In all rats, LpL activity reached a stable base-
line by 12 min and no subsequent changes in released activity
were observed. We corrected LpL activity for perfusion
rate and heart weight to determine LpL secretion rate.
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Figure 1 | In vivo heparin releasable LpL in control, NS, and Analb
rats. Serum was obtained prior after a 12-h fast followed by injection
of 50 U/kg heparin was injected into the femoral vein. The animal was
exsanguinated 5 min later and LpL activity was measured. The mean
of LpL activity in control, NS, and Analb rats are shown7s.e.m.
wPo0.0001.
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Figure 2 | LpL pools in perfused hearts. Release of LpL activity into
perfusate by control, NS, and Analb hearts upon perfusion with
5 U/ml heparin. Zero minutes represent the time of heparin addition
to the perfusate. LpL activity in control perfusate (m) has an initial
peak representing LpL bound to heparan sulfate glycosaminoglycans
on vascular endothelial cells, a second smaller peak representing
LpL bound to heparan sulfate on myocardial cells, and a final stable
baseline representing the endogenous rate of LpL secretion by
myocardial cells. The other lines represent release by a typical
nephrotic ( ) or Analb ( ) heart. Noticeably, there was either a very
small or a nonexistent initial peak in hearts from NS and Analb
animals. The second peak was fused with the first in three control,
and was indistinguishable in all NS and Analb hearts.
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Bagby attributes the two initial peaks and the stable baseline
to 1: endothelial bound LpL, 2: vesicular or interstitial LpL,
and 3: the endogenous rate of LpL synthesis.24 More recent
research indicates that Golgi-LpL not directed to lysozomal
degradation is exocytosed and binds to heparan sulfate
moieties on the cell surface.13,25 This suggests that the second
LpL peak is indicative of the interstitial LpL pool and the
final, stable release indicates the rate of cellular secretion, to
the interstitial and endothelial pools.
The quantitation of these pools is represented by the bar
graphs in Figure 3. Figure 3a depicts quantitatively the
endothelial and interstitial pool sizes while Figure 3b
represents the cellular secretion rate. The specific endothelial
associated LpL pool was reduced in NS rats to 23.9%
of control (control¼ 1206171559; NS¼ 288571077;
Analb¼ 356572277 nmol/ml perfusate/g heart; Po0.05).
No differences were detected in the interstitial pool
(control¼ 34177686; NS¼ 27147748; Analb¼ 38847
2836), or in the cellular secretion rates (control¼ 7977102;
NS¼ 593779; Analb¼ 5097117).
LpL mRNA levels in heart tissue
We found no differences in the levels of LpL mRNA in NS
rats compared to controls (Figure 4). Levels of LpL mRNA
in NS rats tended to be only slightly reduced compared
to control (Neph¼ 0.9570.23, Analb¼ 0.7170.03, Con¼
1.0470.17 LpL/GA3PDH).
Binding of exogenous 125I-LpL to cultured aortic
endothelial cells
The binding of exogenous LpL to cultured rat aortic
endothelial cells (RAEC) was significantly reduced in cells
treated with serum from nephrotic animals compared to
serum from control (Figure 5) (Po0.0001). We tested
whether this effect of nephrotic syndrome persisted in the
absence of proteinuria and of severe hypertriglyceridemia.
Binding of LpL to RAEC treated with serum from Analb was
also reduced compared to control (Po0.0001) and was not
different from treatment with nephrotic serum.
DISCUSSION
The reduction of LpL in NS rats is a consequence of a specific
reduction of LpL at the vascular endothelial surface. This
reduction is not the result of decreased synthesis or release of
LpL from mesenchymal tissue since interstitial LpL levels are
normal, interstitial cell LpL secretion is normal, and LpL
mRNA levels are normal in rat heart tissue regardless of
animal origin. Additionally we previously demonstrated that
residual LpL activity in cardiac muscle in NS and normal rats
is the same following perfusion with heparin.8 Thus, the
reduction in cardiac LpL pool is confined to heparin labile
LpL, the fraction bound to endothelial and interstitial cell
glycosaminoglycans. The bulk of LpL clearly resides in
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Figure 3 | Quantitation of LpL peaks and secretion rate. For each
heart, the area under the first and second peak was determined and
is represented in the first graph: control, NS, and Analb. The
endogenous LpL secretion is represented in the second graph.
The data shown are mean7s.e.m. wPo0.0001.
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Figure 4 | Expression of myocardial LpL by quantitative PCR.
Levels of mRNA in control, NS, and Analb hearts were measured
by quantitative PCR after perfusion. The ratio of LpL to GA3PDH was
determined. No differences in the relative levels of LpL mRNA were
observed.
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Figure 5 | Binding of exogenous 125I-LpL to serum treated RAEC.
Binding of LpL was measured after treatment of cells with media
containing 20% serum from control, NS, or Analb animals. Cells were
grown to confluence with 20% fetal bovine serum and treated with
serum experimental serum for 18 h prior to determination of LpL
binding. Specific LpL binding was assessed by competition of 125I-LpL
with unlabeled LpL.
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noncardiac tissues, including skeletal muscle and adipose
tissue. While the heart might not be quantitatively repre-
sentative of all LpL pools, total body heparin releasable LpL
was decreased to at least a similar extent to what we observed
in the heart. Thus, it is likely that similar changes in LpL
release occur in other tissues. Glycosaminoglycans, including
both heparin and heparan sulfate, bind to and stabilize
LpL.15,25 Since we perfused isolated hearts with heparin, it is
possible that we provided a more protective environment
than exists in vivo and failed to detect loss of LpL activity
during the translocation from cardiac myocytes and delivery
to capillary endothelial cells. Our observation that serum
from hypoalbuminemic NS or Analb animals decreases LpL
binding to endothelial cells makes such a hypothesis
unnecessary. We propose that the decrease in endothelial
bound LpL is the result at least in part of decreased LpL
binding to endothelial cells, and furthermore that these
alterations are a consequence of hypoalbuminemia or
reduced plasma oncotic pressure (p) and does not require
proteinuria.
We found that heparin releasable LpL activity is a
significant predictor of serum TG in NS animals, suggesting
a critical role for LpL in TRL catabolism in the NS. While
heparin releasable LpL predicted serum TG in NS it did not
do so in normal rats; however, LpL is present in great excess
in normal animals. What is of interest is that TG levels are
only slightly increased in Analb even though LpL is reduced
to the same extent in these animals as it is in nephrotic
animals. We have hypothesized previously that proteinuria
confers an additional defect on VLDL structure not resulting
from decreased albumin levels alone, rendering its binding to
endothelial bound lipase to be reduced.
Our current observations provide a link between altered
lipoprotein metabolism that is independent of proteinuria,
and insufficient in the absence of altered lipoprotein
structure, to cause great increases in TG levels. Nevertheless,
hypoalbuminemia in these models induces one component of
reduced lipoprotein catabolism that is independent of
proteinuria. When this component is linked to altered
lipoprotein structure caused by proteinuria then significant
TG levels result.
Proteinuric rats have a combined defect that results in
delayed clearance of TRL.10,11 Proteinuria alters VLDL
structure such that binding to LpL is impaired. Clearance
of TRL therefore is of increased dependence upon a rich
endothelial bound LpL pool. Thus in NS, the level of
endothelial bound LpL clearly presents a dose dependent
barrier to TRL clearance.
The LpL depletion in NS rats is unlikely to be due to
changes in gene expression. We found no difference in LpL
mRNA levels in hearts from rats with nephrotic syndrome
induced by adriamycin. Liang and Vaziri26 did note a
difference in LpL mRNA in hearts obtained from rats
rendered nephrotic with puromycin aminonucleoside, but
not in other tissues. They hypothesized the presence of a
defect distal to mRNA processing.
Endothelial LpL levels are not normally regulated at the
level of LpL gene expression, and our findings also indicate
that changes in expression are not necessary for depletion of
endothelial LpL pools. If reduced expression of the LpL gene
were the only mechanism responsible for its depletion on the
vascular endothelium, one would anticipate that release of
this protein as well as its level in all tissue compartments
would be reduced. Our previous observation that residual
tissue bound LpL was the same in hearts from nephrotic and
control animals while heparin releasable Lpl was significantly
reduced in hearts from nephrotic animals is consistent with
this hypothesis.8
We next established that the depleted LpL pool that is
depleted is the endothelial pool, and that the interstitial pool is
not depleted, suggesting that LpL is both synthesized and
released by the heart in nephrotic and control animals at
similar rates. The principal LpL pool depleted is that bound to
the vascular endothelium, suggesting that there is either a defect
in its binding to the vascular endothelium in the presence of
low albumin, or that LpL once bound is rapidly destroyed.
We tested the hypothesis that LpL binding to the vascular
endothelium is reduced by serum from animals with
low albumin levels regardless of whether or not proteinuria
was present. Specifically, endothelial cells pretreated with NS
or Analb serum have reduced binding to the vascular
endothelium.
There are a number of possible mechanisms for this
reduced LpL binding. First, LpL’s association with heparan
sulfate stabilizes the enzyme.15 LpL binds to specific
glycosylation sequences, which may change or whose number
may be reduced in the nephrotic syndrome. Evidence for
proteoglycan changes in nephrotic syndrome are abun-
dant.27–29 Alternatively, Pang et al.30 have identified an N-
terminal fragment of apoB that is synthesized in endothelial
cells and is released to the lumen surface where it increases
LpL binding. Finally, Pillarisetti et al.15 also report that
circulating levels of lyso-phosphatidyl choline (LPC) alter the
binding affinity of LpL to heparan sulfate proteoglycans.
Sasaki and Goldberg31 demonstrated that 3% albumin
prevented a defect in the binding of LpL to heparan sulfate
proteoglycan caused by LPC. However, Joles32,33 observed
that free LPC levels were not increased in Analb making such
a mechanism difficult to invoke as a cause of the changes that
we observed. Nevertheless, we have not directly established
the mechanism whereby the presence or absence of albumin
in serum causes reduced lipase on an endothelial surface. The
presence of a substance that is normally bound by albumin
that inhibits lipase binding is clearly one potential mechan-
ism. It is possible that that reduced LpL or apoE reduces
heparan sulfate proteoglycan since both these proteins have
been demonstrated to enhance proteoglycan production.34
The particular dynamics of our findings limit the expectation
that reduced apoE or LpL are the source and altered heparan
sulfate proteoglycan is the consequence. LpL secretion is not
reduced. Analb rats have normal lipoprotein apoE content,
unlike proteinuric rats whose lipoproteins are apoE depleted.
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This is true even of mildly proteinuric animals with normal
plasma lipids.35 Changes in any of these parameters in the
nephrotic syndrome could result in defective LpL binding
and/or stability at the vascular endothelium.
MATERIALS AND METHODS
Animals
Studies were approved by the Animal Review Committee at the
University of California Davis and the Department of Veterans
Affairs. Rats were all male Sprague–Dawley obtained from Simenson
Farms (Hayward, CA, USA). They were kept in 24 h light/dark
rooms and fed ad libitum. Nephrotic syndrome was induced at 5
weeks of age by tail vein injection of 5 mg/kg adriamycin
(Adriamycin RDF: Pharmacia & Upjohn, Milan, Italy). Urinary
albumin excretion was measured 4 weeks after injection with
adriamycin and rats with albuminuria of 4350 mg/day were
selected. In each experiment, rats were anesthetized with an
intraperitoneal injection of 0.75 g/kg (control) or 0.40 g/kg
(nephrotic) sodium pentobarbital. No heparin was used.
Quantitative reverse transcriptase-polmerase chain reaction
RNA was isolated from hearts of three control, three NS, and three
Analb rats. The heart was immediately frozen in liquid nitrogen and
stored at 701C until extracted. RNA was extracted with Trizol
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s
protocol and dissolved in DEPC-treated water. RNA (1mg) was
incubated for 30 min with 1 U DNase I (Invitrogen) to digest
contaminating genomic DNA, then reversed transcribed using 200 U
M-MLV reverse transcriptase (Invitrogen) and 0.5 mg oligo-dT
primer (Invitrogen) in a buffer containing 1 mM dNTP’s (Promega,
Madison, WI, USA), 3 mM MgCl2, and 7 U RNase inhibitor
(Invitrogen). Quantitative polymerase chain reaction (PCR) was
performed using a GeneAmp 5700 Sequence Detection System (PE
Applied Biosystems, Foster City, CA, USA) using SYBR Green I
(Invitrogen) for fluorescent detection of the double-stranded PCR
products. Each 50ml reaction contained 10 pmol of each primer,
200mM dNTP’s, 1.25 U HotStartTaq DNA polymerase (Qiagen,
Valencia, CA, USA), 5 ml SYBR Green I diluted 1:1000 in DMSO,
1.5 mM MgCl2, and buffer supplied with the DNA polymerase. The
primer sequences for LpL were 50-GCA GGA AGT CTG ACC AAC
AAG-30(forward) and 50-CTT CAC CAG CTG GTC CAC AT-30
(reverse). The primer sequences for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were 50-CTG GAG AAA CCT GCC AAG
TAT GAT-30 (forward) and 50TTC TTA CTC CTT GGA GGC CAT
GTA-30(reverse). The relative degree of LpL expression in treated
animals vs controls was determined by comparing the cycle number
at which a specified threshold fluorescence emission from the
294 bp LpL PCR product was achieved, Ct
LpL, normalized to the
Ct
GAPDH of the 267 bp GAPDH PCR product for each cDNA sample.
The relative level of LpL expression is calculated by
2ðCtLpLCtGAPDHÞ treated=ðCtLpLCtGAPDHÞcontrol.
Purification of LpL
LpL was purified using the methods of Liu et al.36 Briefly, raw skim
milk, 0.4 M NaCl was incubated at 41C over night with heparin-
Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Heparin sepharose was loaded onto into an XK-26 column
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and rinsed
with 20 mM Tris, pH 7.4, 20% glycerol, 0.5 M NaCl buffer followed by
0.75 M NaCl until the absorbance at 280 nm reached background.
LpL was eluted with 1.5 M NaCl and the fractions with an optical
density of X(0.200 AU) at 280 nm were subsequently analyzed by
SDS-PAGE. Fractions containing a single darkly staining band at
55 kDa were pooled.
LpL activity
LpL activity was assessed using a protocol adapted from Krauss
et al.37 In total, 10 mCi of 3H-triolein, 1.5 mg phosphatidyl choline,
and 37.5 mg triolein in chloroform solution were combined in a
50 16 mm2 tube and dried completely under N2. A measure of
2.8 ml substrate buffer (0.2 M Tris, 0.150 M NaCl, pH 8.6), 1.2 ml 10%
fatty acid free bovine serum albumin in substrate buffer, 0.25 ml 1%
Triton X-100 substrate buffer, and 0.25 ml fasting heat inactivated
human plasma were added to the tube. The solution was then
sonicated on ice using a Branson Sonifier 250 for 5 min at power
output 5 and 50% duty.
Emulsion (0.1 ml) was then added to 0.4 ml sample or to sample
diluted with substrate buffer. The samples were incubated for 30 min
at 371C. The reaction was stopped by the addition of 1.62 ml
chloroform/MeOH/heptane (1.25:1.41:1.00) to each tube. The tubes
were vortexed, and 0.50 ml of 0.4 M boric acid/0.4 M K2CO3, pH 10.0
was added. The samples were vortexed again for 15 s and then
centrifuged for 10 min at 1000 g to separate phases. One milliliter of
the top phase was counted in liquid scintillation fluid on a Beckman
Scintillation counter. Emulsion (0.1 ml) was counted as standard for
oleic acid release and an LpL standard curve was generated using
purified LpL. The curve was linear with respect to LpL mass.
Samples from in vivo measurements of heparin releasable LpL also
contain hepatic lipase. We used 1.0 M NaCl to inhibit LpL activity
and plasma LpL was measured as the difference between lipase
activity in the absence and in the presence of 1.0 M NaCl.
In vivo heparin releasable LpL activity
In order to establish the effect of reduced serum albumin on total
heparin releasable LpL, five nephrotic, five Analb, and five control
animals were injected intravenously with 50 U/kg heparin. After
5 min, the rats were exsanguinated by aortic puncture. Blood was
collected into tubes containing ethylenediaminetetraacetic acid and
the plasma was collected and stored at 701C until assayed for LpL
activity.
Perfusion of hearts
Eight control, six NS, and six Analb animals were used. The hearts
were excised and perfused retrograde with Krebs–Henseleit bicarbo-
nate buffer (pH 7.4) containing 1% albumin and 4.0 g/l glucose by
the method of Langendorff. The perfusate and the perfusate chamber
were kept at 371C. Flow was maintained at 7 ml/min/g heart and the
perfusate was not recirculated. The heart rate was monitored every
10 min for deterioration of heart rate. Hearts with declining heart
rates were rejected. For the first 5 min, residual blood was washed
out. Afterwards, the perfusate pool was switched to one containing
perfusate bufferþ 5 U/ml heparin, an amount which causes maximal
release of LpL.38 Perfusate fractions were collected from 2 min prior
to heparin perfusion until 15-min postheparin perfusion. After
15 min, perfusate was collected at 5 min intervals for 30 min. The
fractions were stored at 701C until assayed for LpL activity.
Cells
A primary culture of RAEC was obtained by the method of McGuire
and Orkin39 from a control rat. The thoracic aorta was gently
removed, cleaned, and sliced into 2–3 mm sections under sterile
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conditions. These sections were laid onto a layer of Matrigel
(Becton-Dickinson, Bedford, MA, USA) in a 24-well cluster plate,
which had been preconditioned for 1 h with E-STIM (BD
Biosciences, San Diego, CA, USA) endothelial cell growth medium
(Becton-Dickinson) supplemented with epidermal growth factor
and endothelial cell growth supplement. After 8 days of growth, the
explants were removed and remaining cells were allowed to grow for
an additional week whereupon they exhibited cobblestone mor-
phology typical of endothelial cells. The cells were removed from the
Matrigel by incubation with 2% dispase for 30 min and passed into a
25-cm2 tissue culture flask coated with collagen I. The cells were
thereafter grown on collagen I under the aforementioned growth
supplement. Due to the presence of smooth muscle cells, the cells
were trypsinized, and diluted for single-cell cloning by passage into
48-well cluster plates. A subclone staining negative for a-smooth
muscle actin and positive for uptake of acetylated DiI-LDL was
selected for further expansion and thereafter grown with Dulbecco’s
modified Eagle’s medium supplemented with 20% fetal bovine
serum, and 20 mM glycine.
LpL binding to cultured RAEC
Bovine LpL was iodinated by the method of McFarlane as modified
by Helmkamp et al.40 Iodinated LpL was dialyzed exhaustively with
20 mM Trisþ 20% glycerol, pH 7.4 until the counts were 98%
precipitable by trichloroacetic acid. For binding studies, RAEC at
passage 12 were plated into 48-well plates and experiments were
performed 1–2 days after reaching confluence. Serum from five
control rats was pooled. In total, 10% dilution of this pool in
DMEM was used to replace fetal bovine serum for 18 h prior to
incubation with LpL after the cells had reached confluence.
Similarly, pools of five NS or five Analb rats were used in the
experimental assays.
Media containing DMEM, 25 mM N-2-hydroxyethylpiperazine-
N0-2-ethanesulphonic acid pH 7.4, and lipoprotein deficient fetal
bovine serum was used to prepared appropriate concentrations of
labeled and unlabeled LpL. Prior to assaying binding, some wells were
incubated with 1.0 Sigma U/ml heparitinase (Seikagaku) for 1 h. To
solutions containing 0.5mg/ml 125I-LpL, unlabeled LpL was added to
achieve total LpL protein concentrations of between 0.5 and 6mg/ml.
Wells containing 5 U/ml heparin were used to assess nonspecific
binding. Forty eight-well plates were removed from incubators and
allowed to cool on ice for 30 min. LpL containing media (0.125 ml)
was added to wells and each concentration was assayed in triplicate.
Plates were gently shaken for 4 h at 41C. The cells were then rinsed
3 with DMEMþ 2 mg/ml albumin at 41C, incubated 2 for
10 min with DMEMþ 2 mg/ml albumin at 41C, and rinsed twice
times with DMEM at 41C. Finally, the cells were dissolved in 0.25 ml
0.1 M NaOH and counted on a Packard gamma counter.
Statistical analysis
The data were analyzed using GraphPad Prism version 4.00 for
Windows, GraphPad Software, San Diego, CA, USA, www.graphpad.
com. Differences were determined using Student’s t-test and
correlation was determined using the least-squares method.
Differences in slope were determined using an F-test to calculate
the P-value. All data are reported mean7s.e.m.
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